Suppr超能文献

伴有门静脉高压的肝门-肝窦状隙血管疾病:自然病程与长期预后

Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome.

作者信息

Magaz Marta, Giudicelli-Lett Heloïse, Abraldes Juan G, Nicoară-Farcău Oana, Turon Fanny, Rajoriya Neil, Goel Ashish, Raymenants Karlien, Hillaire Sophie, Téllez Luis, Elkrief Laure, Procopet Bogdan, Orts Lara, Nery Filipe, Shukla Akash, Larrue Hélène, Degroote Helena, Aguilera Victoria, Llop Elba, Turco Laura, Indulti Federica, Gioia Stefania, Tosetti Giulia, Bitto Niccolò, Becchetti Chiara, Alvarado Edilmar, Roig Cristina, Diaz Raquel, Praktiknjo Michael, Konicek Anna-Lena, Olivas Pol, Fortea José Ignacio, Masnou Helena, Puente Ángela, Ardèvol Alba, Navascués Carmen A, Romero-Gutiérrez Marta, Scheiner Bernhard, Semmler Georg, Mandorfer Mattias, Damião Filipe, Baiges Anna, Ojeda Asunción, Simón-Talero Macarena, González-Alayón Carlos, Díaz Alba, García-Criado Ángeles, De Gottardi Andrea, Hernández-Guerra Manuel, Genescà Joan, Drilhon Nicolas, Noronha Ferreira Carlos, Reiberger Thomas, Rodríguez Manuel, Morillas Rosa María, Crespo Javier, Trebicka Jonel, Bañares Rafael, Villanueva Càndid, Berzigotti Annalisa, Primignani Massimo, La Mura Vincenzo, Riggio Oliviero, Schepis Filippo, Verhelst Xavier, Calleja José Luis, Bureau Christophe, Albillos Agustín, Nevens Frederik, Hernández-Gea Virginia, Tripathi Dhiraj, Rautou Pierre-Emmanuel, García-Pagán Juan Carlos

机构信息

Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). CIBEREHD (Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas). Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE-Liver). Departament de Medicina i Ciències de la Salut. Universitat de Barcelona, Barcelona, Spain.

Université de Paris-Cité, Inserm, Centre de recherche sur l'inflammation, UMR 1149, Paris, France; AP-HP, Hôpital Beaujon, Service d'Hépatologie, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVER, Clichy, France.

出版信息

J Hepatol. 2025 Jan;82(1):72-83. doi: 10.1016/j.jhep.2024.07.035. Epub 2024 Aug 22.

Abstract

BACKGROUND & AIMS: Current knowledge of the natural history of patients with porto-sinusoidal vascular disorder (PSVD) is derived from small studies. The aim of the present study was to determine the natural history of PSVD and prognostic factors in a large multicenter cohort of patients.

METHODS

We performed a retrospective study on patients with PSVD and signs of portal hypertension (PH) prospectively registered in 27 centers.

RESULTS

A total of 587 patients were included, median age of 47 years and 38% were women. Four-hundred and one patients had an associated condition, which was graded as severe in 157. Median follow-up was 68 months. At diagnosis, 64% of patients were asymptomatic while 36% had a PH-related complication: PH-related bleeding in 112 patients, ascites in 117, and hepatic encephalopathy in 11. In those not presenting with bleeding, the incidence of first bleeding was 15% at 5 years, with a 5-year rebleeding rate of 18%. The 5-year cumulative incidence of new or worsening ascites was 18% and of developing portal vein thrombosis was 16%. Fifty (8.5%) patients received a liver transplantation and 109 (19%) died, including 55 non-liver-related deaths. Transplant-free survival was 97% and 83% at 1 and 5 years, respectively. Variables independently associated with transplant-free survival were age, ascites, serum bilirubin, albumin and creatinine levels at diagnosis and severe associated conditions. This allowed for the creation of a nomogram that accurately predicted prognosis.

CONCLUSIONS

The prognosis of PSVD is strongly determined by the severity of the associated underlying conditions and parameters of liver and renal function.

IMPACT AND IMPLICATIONS

Porto-sinusoidal vascular liver disorder (PSVD) is a rare entity that usually affects young people, frequently causes severe complications of portal hypertension, and may reduce life expectancy. To date, there is scarce information regarding its clinical manifestations, natural history and prognostic factors. The present study, including the largest number of patients with PSVD reported so far, shows that overall, when managed at centers of expertise, the prognosis of patients with PSVD is good, with LT-free survival rates of 83% and 72% at 5 and 10 years, respectively. Presence and severity of an underlying associated condition, presence of ascites, age and bilirubin, albumin and creatinine levels were associated with poor prognosis. These results are important to know for hepatologists. A final model combining these parameters enabled development of a nomogram that predicts prognosis with good discrimination and calibration capacity and can be easily applied in clinical practice.

摘要

背景与目的

目前关于门静脉窦状血管疾病(PSVD)患者自然史的认识来自于小型研究。本研究的目的是确定一大群多中心PSVD患者的自然史和预后因素。

方法

我们对前瞻性登记在27个中心的PSVD及门静脉高压(PH)体征患者进行了一项回顾性研究。

结果

共纳入587例患者,中位年龄47岁,38%为女性。401例患者有相关疾病,其中157例为重度。中位随访时间为68个月。诊断时,64%的患者无症状,36%有PH相关并发症:112例患者发生PH相关出血,117例出现腹水,11例发生肝性脑病。在未出现出血的患者中,5年时首次出血发生率为15%,5年再出血率为18%。新发或恶化腹水的5年累积发生率为18%,门静脉血栓形成的发生率为16%。50例(8.5%)患者接受了肝移植,109例(19%)死亡,其中55例为非肝脏相关死亡。1年和5年的无移植生存率分别为97%和83%。与无移植生存独立相关的变量包括诊断时的年龄、腹水、血清胆红素、白蛋白和肌酐水平以及严重相关疾病。据此创建了一个能准确预测预后的列线图。

结论

PSVD的预后很大程度上取决于相关基础疾病的严重程度以及肝脏和肾功能参数。

影响与意义

门静脉窦状血管性肝病(PSVD)是一种罕见疾病,通常影响年轻人,常导致门静脉高压的严重并发症,并可能缩短预期寿命。迄今为止,关于其临床表现、自然史和预后因素的信息很少。本研究包括了迄今为止报道的最多数量的PSVD患者,结果表明,总体而言,在专业中心进行管理时,PSVD患者的预后良好,5年和10年的无肝移植生存率分别为83%和72%。基础相关疾病的存在和严重程度、腹水的存在、年龄以及胆红素、白蛋白和肌酐水平与预后不良相关。这些结果对肝病学家来说很重要。结合这些参数的最终模型能够开发出一种列线图,该列线图具有良好的辨别力和校准能力来预测预后,并且可以很容易地应用于临床实践。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验